Allakos (ALLK) said Thursday results of a phase 1 trial showed that a subcutaneously administered AK006, its investigational monoclonal antibody that selectively inhibits mast cells, was "well-tolerated with a favorable safety profile."
The company reported data from single dose subcutaneous AK006 up to 720 milligrams, with skin biopsies taken from treated healthy volunteers showing high levels of receptor occupancy, confirming that AK006 reached skin tissue mast cells. The results were consistent with the trial of intravenously-administered AK006, it said.
The results showed there were no serious adverse events in subjects, no treatment emergent adverse events leading to discontinuation of AK006, and no dose limiting toxicities, Allakos said.
The company expects topline phase 1 results of intravenous AK006 in patients with chronic spontaneous urticaria in early Q1 next year.
Shares of the company were advancing over 7% in extended trading.
Price: 0.7076, Change: +0.05, Percent Change: +7.37
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。